Compare Elder Pharma with Sanofi India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA SANOFI INDIA ELDER PHARMA/
SANOFI INDIA
 
P/E (TTM) x -0.2 41.9 - View Chart
P/BV x 0.1 8.5 1.2% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 ELDER PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
SANOFI INDIA
Dec-18
ELDER PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3806,840 5.6%   
Low Rs1884,630 4.1%   
Sales per share (Unadj.) Rs491.21,203.1 40.8%  
Earnings per share (Unadj.) Rs-3.2165.3 -1.9%  
Cash flow per share (Unadj.) Rs14.4209.9 6.9%  
Dividends per share (Unadj.) Rs084.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs376.5963.6 39.1%  
Shares outstanding (eoy) m20.5423.03 89.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.64.8 12.1%   
Avg P/E ratio x-89.334.7 -257.2%  
P/CF ratio (eoy) x19.727.3 72.1%  
Price / Book Value ratio x0.86.0 12.7%  
Dividend payout %050.8 0.0%   
Avg Mkt Cap Rs m5,833132,078 4.4%   
No. of employees `000NA3.3 0.0%   
Total wages/salary Rs m2,1794,068 53.6%   
Avg. sales/employee Rs ThNM8,393.8-  
Avg. wages/employee Rs ThNM1,232.4-  
Avg. net profit/employee Rs ThNM1,153.0-  
INCOME DATA
Net Sales Rs m10,08927,708 36.4%  
Other income Rs m257897 28.6%   
Total revenues Rs m10,34628,605 36.2%   
Gross profit Rs m-7926,235 -12.7%  
Depreciation Rs m3611,027 35.2%   
Interest Rs m2,7567 39,375.7%   
Profit before tax Rs m-3,6536,098 -59.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1252,292 5.5%   
Profit after tax Rs m-653,806 -1.7%  
Gross profit margin %-7.822.5 -34.9%  
Effective tax rate %-3.437.6 -9.1%   
Net profit margin %-0.613.7 -4.7%  
BALANCE SHEET DATA
Current assets Rs m9,24015,922 58.0%   
Current liabilities Rs m9,9986,235 160.3%   
Net working cap to sales %-7.535.0 -21.5%  
Current ratio x0.92.6 36.2%  
Inventory Days Days4664 72.8%  
Debtors Days Days6021 287.3%  
Net fixed assets Rs m10,1247,539 134.3%   
Share capital Rs m206230 89.4%   
"Free" reserves Rs m5,58221,962 25.4%   
Net worth Rs m7,73422,192 34.8%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88229,839 76.7%  
Interest coverage x-0.3872.1 -0.0%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.9 47.5%   
Return on assets %11.812.8 92.0%  
Return on equity %-0.817.2 -4.9%  
Return on capital %22.327.5 81.1%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m3077,587 4.0%   
Fx outflow Rs m1257,145 1.8%   
Net fx Rs m181442 41.0%   
CASH FLOW
From Operations Rs m11,7543,739 314.4%  
From Investments Rs m-561-731 76.7%  
From Financial Activity Rs m-6,762-1,972 342.9%  
Net Cashflow Rs m4,4321,036 427.8%  

Share Holding

Indian Promoters % 39.6 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 7.5 14.4 52.1%  
FIIs % 16.8 14.6 115.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 10.5 343.8%  
Shareholders   16,479 15,184 108.5%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   FULFORD INDIA  VENUS REMEDIES  CIPLA  WOCKHARDT  AUROBINDO PHARMA  

Compare ELDER PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY20); Net Profit Down 8.1% (Quarterly Result Update)

May 21, 2020 | Updated on May 21, 2020

For the quarter ended March 2020, SANOFI INDIA has posted a net profit of Rs 854 m (down 8.1% YoY). Sales on the other hand came in at Rs 8 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS